NF1 and neoplasm: In the studied cohort, Tier IA predictors were rare (agnostic BRAF p.V600E and tumor-specific NF1 aberrations), while Tier IB–II predictors (i.e., mentioned in single studies on possible benefits of TT and/or warranting enrollment in a clinical trial for TT in other tumor types, mostly adult) were common, including ALK, BRCA1/2, PIK3CA, PDGFRB, TSC2 and KIT variants.